0001735276-21-000013.txt : 20210216 0001735276-21-000013.hdr.sgml : 20210216 20210216160849 ACCESSION NUMBER: 0001735276-21-000013 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210211 FILED AS OF DATE: 20210216 DATE AS OF CHANGE: 20210216 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MARAGANORE JOHN CENTRAL INDEX KEY: 0001180432 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36407 FILM NUMBER: 21638307 MAIL ADDRESS: STREET 1: 75 SIDNEY ST CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ALNYLAM PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001178670 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770602661 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 675 WEST KENDALL STREET STREET 2: HENRI A. TERMEER SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (617) 551-8200 MAIL ADDRESS: STREET 1: 675 WEST KENDALL STREET STREET 2: HENRI A. TERMEER SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: ALNYLAM PHARMACEUTICALS INC DATE OF NAME CHANGE: 20020724 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2021-02-11 0 0001178670 ALNYLAM PHARMACEUTICALS, INC. ALNY 0001180432 MARAGANORE JOHN 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MA 02142 1 1 0 0 Chief Executive Officer Common Stock 2021-02-11 4 A 0 14166 0.0 A 211755 D Common Stock 2021-02-12 4 F 0 5412 156.0 D 206343 D Common Stock 2021-02-12 4 F 0 307 151.937 D 206036 D Common Stock 3133 I by Managed Account Performance Stock Option 2017 (right to buy) 119.13 2021-02-11 4 A 0 17504 0.0 A 2021-02-11 2028-03-01 Common Stock 17504 52500 D On February 28, 2019, the reporting person was granted performance-based restricted stock units (PSU) in connection with the 2018 year-end compensation review. One third of the PSU award vests upon the achievement of each of three specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the second performance criterion was met and an additional one-third of the PSU award vested as of February 11, 2021. Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. On March 1, 2018, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock in connection with the 2017 year-end compensation review. One third of the shares subject to the option vests upon the achievement of each of three specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the third performance criterion was met and the option vested as to the final one third of the shares as of February 11, 2021. By: /s/ Mary Beth DeLena, Attorney-in-Fact For: John M. Maraganore 2021-02-16